文献速递肝病消化道肿瘤与早癌

NRF2-COX2-PGE2轴驱动肝细胞癌免疫冷肿瘤并预测联合免疫治疗耐药

NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2026-01-15

该研究通过基因异质性免疫健全小鼠模型及多队列人类数据,发现肿瘤内在NRF2-COX2-PGE2轴激活驱动免疫冷肿瘤微环境并介导阿替利珠单抗联合贝伐珠单抗耐药。高NRF2活性预测更短无进展生存期,血浆PGE2可独立预测不良应答和生存,COX2抑制剂联用与更长PFS相关。

要点

  • NRF2-COX2-PGE2轴激活驱动HCC免疫冷微环境并介导Atez/Bev耐药。
  • 高NRF2活性预测更短PFS,血浆PGE2可独立预测不良应答和生存。
  • COX2抑制剂联用与更长PFS相关,靶向该通路可能增强疗效。

核心结论

  • 肿瘤内在NRF2-COX2-PGE2轴激活驱动免疫冷TME并介导HCC对Atez/Bev耐药,靶向该通路可能增强疗效,血浆PGE2可作为无创分层生物标志物。

研究设计与样本

  • 研究使用经水动力注射条形码癌基因库生成的基因异质性免疫健全HCC小鼠模型,整合单细胞RNA测序、空间转录组学及人HCC组织bulk RNA测序。
  • 回顾性分析纳入多机构注册的549例Atez/Bev治疗患者和199例手术切除HCC患者。
  • 外部验证使用IMbrave150和GO30140试验注册的247例患者RNA-seq数据。

主要发现

  • 小鼠中Atez/Bev消除热肿瘤,而预先存在的冷肿瘤伴耗竭效应T细胞和Tregs后期占主导。
  • 条形码分析显示耐药肿瘤中NFE2L2(NRF2)富集,NRF2过表达抑制免疫浸润并导致耐药,NRF2或COX2抑制可逆转。
  • 人类队列中无应答者和获得性耐药患者均显示高NRF2/COX2表达和免疫排斥,经空间图谱证实。
  • 高NRF2活性预测更短PFS,同时使用COX2抑制剂与更长PFS相关,血浆PGE2独立预测不良应答和生存。
  • IMbrave150/GO30140中NRF2和前列腺素通路激活与Atez/Bev耐药相关,但与索拉非尼应答无关。

关键数值与推荐

  • 549例Atez/Bev治疗患者和199例手术切除HCC患者纳入回顾性分析。
  • 247例IMbrave150和GO30140试验注册患者RNA-seq数据用于外部验证。
  • 高NRF2活性预测更短PFS,同时使用COX2抑制剂与更长PFS相关。
  • 血浆PGE2独立预测不良应答和生存。

临床怎么用

  • 血浆PGE2可作为非侵入性生物标志物用于Atez/Bev治疗分层。
  • 高NRF2/COX2表达或免疫排斥患者可能对Atez/Bev原发或获得性耐药。
  • 靶向NRF2-COX2-PGE2通路或联用COX2抑制剂可能增强Atez/Bev疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Atezolizumab plus bevacizumab (Atez/Bev) is the first-line immunotherapy for advanced hepatocellular carcinoma (HCC), yet many patients show primary or acquired resistance. We aimed to identify tumor-intrinsic mechanisms driving immune cold tumor microenvironments (TMEs) and Atez/Bev resistance. APPROACH AND RESULTS: We used a genetically heterogeneous immunocompetent HCC mouse model generated by hydrodynamic injection of a barcoded oncogene library, integrating single-cell RNA sequencing, spatial transcriptomics, and bulk RNA sequencing of human HCC tissues. Retrospective analyses included a multi-institutional registry of 549 Atez/Bev-treated patients and 199 surgically resected HCC patients. External validation used RNA-seq data from 247 patients registered in the IMbrave150 and GO30140 trials. In mice, Atez/Bev eliminated hot tumors, while pre-existing cold tumors with exhausted effector T cells and Tregs predominated later. Barcode analysis revealed enrichment of NFE2L2 (NRF2) in resistant tumors. NRF2 overexpression suppressed immune infiltration and conferred resistance, which was reversed by NRF2 or COX2 inhibition. In human cohorts, both non-responders and patients with acquired resistance exhibited high NRF2/COX2 expression and immune exclusion, confirmed by spatial profiling. High NRF2 activity predicted shorter progression-free survival (PFS), whereas concomitant COX2 inhibitor use correlated with longer PFS. Plasma prostaglandin E2 (PGE 2 ) independently predicted poor response and survival. In IMbrave150/GO30140, NRF2 and prostaglandin pathway activation correlated with Atez/Bev resistance but not sorafenib response, validating a treatment-specific mechanism. CONCLUSIONS: Tumor-intrinsic activation of the NRF2-COX2-PGE 2 axis drives immune cold TMEs and mediates Atez/Bev resistance in HCC. Targeting this pathway may enhance efficacy, and plasma PGE 2 represents a non-invasive biomarker for stratification.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yamamoto S, Kodama T, Kuwano A, et al. NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma. Hepatology. 2026. PMID: 41538242. doi:10.1097/HEP.0000000000001677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。